Who are Acular LS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Diclofenac diethylamine 1.16% gel, NSAID (Aceclofenac), EC Aspirin 325, Experimental: Aspirin monotherapy, Acetaminophen & Indomethacin, sumatriptan succinate/naproxen sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acular-ls.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Acular LS — Competitive Intelligence Brief

Acular LS (Acular LS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical NSAID. Area: Ophthalmology.

marketed Topical NSAID COX-1, COX-2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Acular LS (Acular LS) — University of Colorado, Denver. Acular LS is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Acular LS TARGET	Acular LS	University of Colorado, Denver	marketed	Topical NSAID	COX-1, COX-2
Diclofenac diethylamine 1.16% gel	Diclofenac diethylamine 1.16% gel	Novartis	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
NSAID (Aceclofenac)	NSAID (Aceclofenac)	Dong-A ST Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
EC Aspirin 325	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Experimental: Aspirin monotherapy	Experimental: Aspirin monotherapy	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) / Antiplatelet agent	COX-1, COX-2
Acetaminophen & Indomethacin	Acetaminophen & Indomethacin	Queen's University	marketed	Analgesic/Anti-inflammatory combination	COX-1, COX-2 (indomethacin); central nervous system analgesic pathways (acetaminophen)
sumatriptan succinate/naproxen sodium	sumatriptan succinate/naproxen sodium	GlaxoSmithKline	marketed	5-HT1B/1D receptor agonist combined with NSAID	5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical NSAID class)

Chang Gung Memorial Hospital · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Mallinckrodt · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acular LS — Competitive Intelligence Brief. https://druglandscape.com/ci/acular-ls. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab